TY - JOUR
AU - A. Morgan
AU - E. Maslova
AU - C. Kallis
AU - I. Sinha
AU - G. Roberts
AU - T. Tran
AU - R. van der Valk
AU - J. Quint
AD - NHLI, Imperial College London, London, UK.
Joint first authors.
BioPharmaceutical Medical, AstraZeneca, Cambridge, UK.
Alder Hey Children's Hospital, Liverpool, UK.
Division of Child Health, University of Liverpool, UK.
University of Southampton Faculty of Medicine, Southampton, UK.
NIHR Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK.
Epidemiology, AstraZeneca, Gaithersburg, MD, USA.
AN - 37101737
BT - ERJ Open Res
C2 - PMC10123517 Maslova, T.N. Tran and R.J.P. van der Valk are employees of AstraZeneca and hold AstraZeneca shares. R.J.P. van der Valk holds shares in GlaxoSmithKline. G. Roberts and I. Sinha received consultancy from AstraZeneca to their institutions for this work. J.K. Quint reports grants from AUK-BLF and The Health Foundation; grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Bayer; and grants from Chiesi, outside the submitted work. J.K. Quint's research group received funding from AstraZeneca for this work.
DO - 10.1183/23120541.00571-2022
DP - NLM
ET - 2023/04/27
LA - eng
M1 - 2
N1 - 2312-0541
Morgan, Ann
Orcid: 0000-0003-4794-0860
Maslova, Ekaterina
Kallis, Constantinos
Sinha, Ian
Roberts, Graham
Orcid: 0000-0003-2252-1248
Tran, Trung N
van der Valk, Ralf J P
Quint, Jennifer K
Orcid: 0000-0003-0149-4869
Journal Article
England
ERJ Open Res. 2023 Apr 24;9(2):00571-2022. doi: 10.1183/23120541.00571-2022. eCollection 2023 Mar.
PY - 2023
SN - 2312-0541 (Print)
2312-0541
T2 - ERJ Open Res
TI - Short-acting β(2)-agonists and exacerbations in children with asthma in England: SABINA Junior
VL - 9
ER -